Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



FDA Irony: Less Data, Longer Review

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

There's nothing like the Food and Drug Administration's archaic system to put a biotech into a tailspin.

Onyx Pharmaceuticals (Nasdaq: ONXX  ) is down 5% today after the FDA accepted its application to market carfilzomib for multiple myeloma, but only gave it a standard review. Many people, myself included, expected a priority review, which would result in a six-month review time instead of the standard 10-month type.

It isn't the four-month delay that's troubling. A couple of months of not selling the drug aren't worth that much to Onyx's valuation. The drop today is over a fear that the drug won't be approved at all with the current data.

Onyx is trying to get carfilzomib approved with just phase 2b data without a control arm. While this is not the most conclusive way to run a trial since there's nothing to compare the results to, these are patients who have already failed other treatments: Takeda and Johnson & Johnson's (NYSE: JNJ  ) Velcade and Celgene's (Nasdaq: CELG  ) Revlimid, among others.

So Onyx turned in less data and got a longer review time. Oh, the irony.

The FDA reserves priority reviews for "drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists." Carfilzomib would certainly seem to fit the latter part of that definition. And the FDA has been handing out priority reviews like free samples at a factory tour lately. Regeneron Pharmaceuticals (Nasdaq: REGN  ) and Bayer got one for Eylea as did Pfizer (NYSE: PFE  ) and Bristol-Myers Squibb's (NYSE: BMY  ) Eliquis.

But the definition is certainly subjective and the agency seems to be concerned about whether carfilzomib's data to date is sufficient to gain an approval. The drug would likely fall under the accelerated approval program, which would grant an approval pending the outcome of further trial. Carfilzomib isn't dead in the water yet, but the lack of a priority review is a sign that the FDA isn't impressed with the drug, which isn't a good sign at the start of a review process.

Onyx is already running a phase 3 trial, so in the worst-case scenario, the FDA rejects carfilzomib and the biotech has to wait until 2013 to submit the data. A four-month delay isn't a major issue, but two years certainly is.

Keep track of Onyx as it tries to get carfilzomib approved by adding it to the Fool's free My Watchlist service. Just click here to get started.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Pfizer, as well as creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 12, 2011, at 4:05 PM, littlemonk01 wrote:

    The FDAs the biggest hold back in the USA of new drugs, anyone that thinks the FDA has TOP people , also believe in Santa. I have been through FDA inspections in the pharm industry. What a bunch of I--ts. These are the EXPERTS?? HA HA. Time for some one in Washington to check out what we have running and making critical decision on new drugs. But who in Washington really knows!!!!???

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1740436, ~/Articles/ArticleHandler.aspx, 10/26/2016 12:38:23 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
ONXX.DL $0.00 Down +0.00 +0.00%
Onyx Pharmaceutica… CAPS Rating: **
BMY $49.55 Up +0.32 +0.65%
Bristol-Myers Squi… CAPS Rating: ****
CELG $97.63 Down -0.44 -0.45%
Celgene CAPS Rating: *****
JNJ $113.96 Up +0.35 +0.31%
Johnson and Johnso… CAPS Rating: ****
PFE $32.28 Up +0.15 +0.47%
Pfizer CAPS Rating: ****
REGN $366.93 Up +4.68 +1.29%
Regeneron Pharmace… CAPS Rating: ****